Apr 12,2021 | Roche Announces Results of Phase 3 Study for Investigational Antibody Cocktail Casirivimab and Imdevimab for the Prevention of COVID-19 | News | CHUGAI PHARMACEUTICAL CO., LTD.

TOKYO, April 12, 2021 — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today regarding results of the phase III REGN-COV 2069 study for the investigational antibody cocktail casirivimab and imdevimab for the prevention of COVID-19.

Please refer to the link below for details of the press release:

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%


More from: | Category: Pharmaceutical Company News